EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model

Ignacio Silva-Llanes, Silvia Rodríguez-López, Pedro González-Naranjo, Eric Del Sastre, Manuela G López, Juan Antonio Páez, Nuria Campillo, Isabel Lastres-Becker

Brain, Behavior, and Immunity · 2025

DOI: 10.1016/j.bbi.2025.03.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025. Verfasst von Ignacio Silva-Llanes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" …. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB2, Frontotemporal Dementia, Cognitive Dysfunction, Pyroptosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tatiana Pérez de Guzmán el Bueno Foundation, Ministerio de Economía y Competitividad, Spain Ministry of Science and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Frontotemporal dementia (FTD) comprises a group of disorders characterized by a progressive decline in behavior or language linked to the degeneration of the frontal and anterior temporal lobes followed by hippocampal atrophy. There are no effective treatments for FTD and for this reason, novel pharmacological targets, such as the endocannabinoid system (ECS), are being explored. Previous results from our laboratory showed a TAUP301L-dependent increase in CB2 receptor expression in hippocampal neurons of a FTD mouse model, alongside the neuroprotective impact of CB2 ablation. In this study, we evaluated the therapeutic potential of a new CB2 antagonist (PGN36) in our TAU-dependent FTD mouse model. Six-month-old mice received stereotaxic injections of an adeno-associated virus expressing human TAUP301L protein (AAV-TAUP301L) into the right hippocampus and were treated daily with PGN36 (5 mg/kg, i.p.) or vehicle for three weeks. By integrating behavioral tests, RNA-seq, qPCR expression analysis, and immunofluorescence in the AAV expressing TAU mouse model, we found that PGN36 treatment reverses key features of the neurodegenerative process triggered by TAUP301L overexpression. PGN36 treatment effectively countered TAUP301L-induced cognitive decline by reducing TAU protein expression levels and restoring markers of synaptic plasticity. Notably, we observed neuroprotection in the dentate gyrus granular layer, which we attribute to the modulation of pyroptosis. This programmed cell death pathway, is triggered by TAUP301L overexpression. PGN36 appears to modulate the pyroptotic cascade, thereby preventing the pyroptosis-induced neuronal loss. These findings collectively underscore the neuroprotective potential of this novel CB2 antagonist treatment against TAU-associated FTD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cannabinoid, CB2Frontotemporal DementiaCognitive DysfunctionPyroptosisAnimalsDisease Models, AnimalMicetau ProteinsHippocampusMaleNeuronsMice, TransgenicHumansMice, Inbred C57BLNeuroprotective Agents

Stichwörter der Autor:innen

CB(2) antagonistsFTDGASDERMIN DNeurodegenerationNeuroinflammationPyroptosisTAU

Substanzen

Receptor, Cannabinoid, CB2tau ProteinsNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" UAM-CSIC, Madrid, Spain; Instituto de Investigación Sanitaria La Paz (…
  • Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid (UAM), Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" UAM-CSIC, Madrid, Spain. Electronic address: silviamaria.rodriguezlope…
  • Instituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain. Electronic address: pedrojgn@iqm.csic.es.
  • Instituto Teófilo Hernando y Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid 28029 Madrid, Spain. Electronic address: ericdelsastre@gmail.com.
  • Instituto Teófilo Hernando y Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid 28029 Madrid, Spain. Electronic address: manuela.garcia@uam.es.
  • Instituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain. Electronic address: jpaez@iqm.csic.es.

Förderung

  • Tatiana Pérez de Guzmán el Bueno Foundation
  • Ministerio de Economía y Competitividad
  • Spain Ministry of Science and Innovation
  • Center for Networked Biomedical Research on Neurodegenerative Diseases

Zitieren

APA

Silva-Llanes, I., Rodríguez-López, S., González-Naranjo, P., Sastre, E. D., López, M. G., Páez, J. A., Campillo, N., & Lastres-Becker, I. (2025). Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2025.03.008

Vancouver

Silva-Llanes I, Rodríguez-López S, González-Naranjo P, Sastre ED, López MG, Páez JA, et al. Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain, Behavior, and Immunity. 2025. doi:10.1016/j.bbi.2025.03.008

BibTeX
@article{SilvaLlanes2025,
  author = {Silva-Llanes, Ignacio and Rodríguez-López, Silvia and González-Naranjo, Pedro and Sastre, Eric Del and López, Manuela G and Páez, Juan Antonio and Campillo, Nuria and Lastres-Becker, Isabel},
  title = {Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  doi = {10.1016/j.bbi.2025.03.008}
}
Kostenlos starten →